Law360, New York (October 27, 2009) -- The looming prospect of health care reforms and the upcoming expiration of a number of drug patents by 2012 are fueling consolidation in the pharmaceutical industry, with many more companies pushing to do deals with biotechnology firms that have products in the later stages of development, a new report says.
By 2012, drugs representing some $74 billion in sales will lose their patent protection, and companies seeking a way to boost their research and development pipelines and cut costs —...
